Aardvark Therapeutics Activates $150M At-The-Market Offering, Signaling Massive Potential Dilution Amidst Trial Pause

summarizeSummary

Aardvark Therapeutics has filed a prospectus supplement to activate its previously announced At-The-Market (ATM) offering, allowing it to sell up to $150 million of common stock. This move, following a recent Phase 3 trial pause, represents significant potential dilution for existing shareholders.

check_boxKey Events

• Activates $150M At-The-Market Offering

  Aardvark Therapeutics filed a 424B5 prospectus supplement, making its previously announced $150 million At-The-Market (ATM) equity offering program operational.

• Significant Potential Dilution

  The offering allows the company to sell up to $150 million in common stock, which is substantially larger than its current market capitalization, indicating massive potential dilution for existing shareholders.

• Follows Clinical Trial Pause

  This capital raise follows the company's voluntary pause of its Phase 3 HERO and OLE trials on March 23, 2026, due to reversible cardiac observations, highlighting an urgent need for funding.

• Sales Agent and Commission

  Shares will be sold through Piper Sandler & Co. as sales agent, receiving a commission rate of 3.0% of the gross sales price.

auto_awesomeAnalysis

This 424B5 filing finalizes the terms and activates the $150 million At-The-Market (ATM) equity offering program, which was initially registered via an S-3 and detailed in an 8-K on March 23-24, 2026. The ability to sell up to $150 million in common stock is a critical financing step for Aardvark Therapeutics, especially given the recent voluntary pause of its Phase 3 HERO and OLE trials due to cardiac observations. This amount represents a substantial capital raise, significantly exceeding the company's current market capitalization. While securing capital is essential for extending the company's operational runway, the sheer scale of the potential offering implies massive dilution for existing shareholders. Investors should monitor the pace and pricing of ATM sales, as sustained selling could exert downward pressure on the stock price.